Idiopathic Pulmonary Fibrosis (IPF)

Respiratory·MeSH: Idiopathic Pulmonary Fibrosis

Prevalence

18.0 / 100K

Incidence

6.8 / 100K/yr

18 drugs in development·15 companies·8 clinical trials

Drug Pipeline by Phase

Approved(7)

Drug	Company
etorel	GYRE THERAPEUTICS, INC. (GYRE)
nintedanib	X4 Pharmaceuticals, Inc (XFOR)
nintedanib	Aptinyx Inc. (APTX)
nintedanib	NYMOX PHARMACEUTICAL CORP (NYMXF)
nintedanib	DR REDDYS LABORATORIES LTD (RDY)
nintedanib	EXELIXIS, INC. (EXEL)
pirfenidone	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 3(4)

Phase 2(2)

Drug	Company
gri-0621	GRI Bio, Inc. (GRI)
lti-03	Rein Therapeutics, Inc. (RNTX)

Phase 1(2)

Drug	Company
ANPA-0073	Structure Therapeutics Inc. (GPCR)
mnkd-201	MANNKIND CORP (MNKD)

Preclinical(3)

Drug	Company
chit1 small molecule	Ocean Biomedical, Inc. (OCEA)
LTSE-2578	Structure Therapeutics Inc. (GPCR)
REC-4209	RECURSION PHARMACEUTICALS, INC. (RXRX)

BioSniper tracks 18 drugs in development for Idiopathic Pulmonary Fibrosis (IPF) across 15 companies.

There are 8 clinical trials targeting Idiopathic Pulmonary Fibrosis (IPF) tracked by BioSniper.

The estimated prevalence of Idiopathic Pulmonary Fibrosis (IPF) is approximately 18.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.